Supply Chain | April 17, 2026
Syntegon reports record FY25 Results; revenue rises 10% to €1.75 billion
The company allocated €56 million to research and development for next-generation line solutions
The company allocated €56 million to research and development for next-generation line solutions
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Annual EBITDA margin expands by 170 basis points
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Subscribe To Our Newsletter & Stay Updated
